PTC Therapeutics Swings to a Profit on $211 Million in Revenue — Is This Why a Major Fund Just Invested $32 Million?

PTC Therapeutics (NASDAQ:PTCT) saw California-based Palo Alto Investors increase its position by 456,144 shares in the third quarter, adding approximately $33.1 million in value, according to a November 14 SEC filing.Palo Alto Investors disclosed a significant purchase of PTC Therapeutics in its quarterly Form 13-F filed with the Securities and Exchange Commission (SEC) on November 14. The fund boosted its position by 456,144 shares versus the previous quarter, bringing its total to 862,613 shares, with a reported market value of $52.9 million as of September 30.The purchase raises the fund's PTCT stake to 9.8% of its $540.4 million in reportable U.S. equity assets.Continue readingWeiter zum vollständigen Artikel bei MotleyFool Weiter zum vollständigen Artikel bei MotleyFool